Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 5, 2026
Anavex Life Sciences Corp. (AVXL)
A forensic read on Anavex Life Sciences Corp. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Grey Zone
Financial health
42.0
Distress distance
Clean
Earnings quality
2
Forensic signals
-8.0
P / E (ttm)
-48.9%
ROE
$292M
Market cap
0.00%
Dividend yield
-36.1%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Anavex Life Sciences Corp. earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is 42.0, placing it in the Grey zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.
What the filings flag
+3.5%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +11% over the last 3 years to FY2025 (+3.5%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~3.5% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~10%.
247% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 247% of revenue in FY2025 — about $0.14 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 3.5% a year and is falling.
Key fundamentals
Latest Revenue$4.7M
Revenue Growth YoY-36.1%
Net Margin-991.4%
Return on Equity-48.9%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Anavex Life Sciences Corp.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about AVXL's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown